SEC Form 4 · accession 0001553878-15-000009

ALNYLAM PHARMACEUTICALS, INC. · ALNY

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Officer — EVP, R&D, CMO

Period of report

Mar 17, 2015

Accepted (ET)

Mar 19, 2015 · 5:30 pm EDT

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0001178670

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I	Nature of ownership
Common Stock	Mar 17, 2015	M	6,250	$9.30	A	6,250	D
Common Stock	Mar 17, 2015	M	2,500	$7.10	A	8,750	D
Common Stock^F2	Mar 17, 2015	S	1,224	$115.29	D	7,526	D
Common Stock^F3	Mar 17, 2015	S	3,802	$116.34	D	3,724	D
Common Stock^F4	Mar 17, 2015	S	2,080	$117.35	D	1,644	D
Common Stock^F5	Mar 17, 2015	S	1,000	$118.16	D	644	D
Common Stock^F6	Mar 17, 2015	S	644	$119.38	D	0	D
Common Stock^F7	holding	—	—		—	82	I	By Managed Account

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Stock Option (Right to Buy)^F8	$7.10	Mar 17, 2015	M	2,500	D	—	Nov 30, 2021	Common Stock	2,500	7,500	D
Stock Option (Right to Buy)^F8	$9.30	Mar 17, 2015	M	6,250	D	—	Jun 9, 2021	Common Stock	6,250	6,250	D

F1The sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 15, 2013.
F2Sale prices ranged from $114.96 to $115.81.
F3Sale prices ranged from $115.96 to $116.95.
F4Sale prices ranged from $116.97 to $117.72.
F5Sale prices ranged from $117.98 to $118.97.
F6Sale prices ranged from $118.99 to $119.98.
F7The reporting person owns 82 shares of ALNY common stock under the ALNY 401(k) plan as a result of the ALNY 401(k) matching contribution program.
F8The stock option vests as to 25% of the shares on the first anniversary of the grant date and as to an additional 6.25% of the shares each successive three month period thereafter.